Abbvie Inc

NYSE:ABBV   4:00:00 PM EDT
-0.22 (-0.13%)
7:56:31 PM EDT: $163.51 -0.21 (-0.13%)

U.S. FDA Accepts For Priority Review The Biologics License Application For Epcoritamab (Duobody®-Cd3xcd20) For The Treatment Of Relapsed/Refractory Large B-Cell Lymphoma

Published: 11/21/2022 13:06 GMT
Abbvie Inc (ABBV) - U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (duobody®-cd3xcd20) for the Treatment of Relapsed/refractory Large B-cell Lymphoma.